

# Quantitative Monographs

## What happened to Value, and when will it return?

### Equities

Global  
Quantitative

#### "We live in a world where Value isn't working"... don't we?

Wherever you look, whoever you ask – returns to Value have been poor in recent years. Recently we wrote about how [Demographics](#) will lead to lower growth rates in the future – it will be hard to see how we achieve an upward re-rating in valuation multiples in this environment.

#### Free Cash Flow is the potential to pay dividends

Dividend Yield has been king of the Value factors since the 2008 financial crisis. In light of what we know about future growth rates we have investigated several multi-period valuation models that use free cash flow to equity forecasts. We have taken this approach because free cash flow is indicative of the potential to pay dividends and discounted free cash flow to equity valuation serves as a parsimonious framework to remove the impact of accruals on earning power and to estimate intrinsic value.

#### A better mousetrap...

The success of a Value strategy depends greatly on how the factor is defined – those of a defensive nature, that focus on the ability of firms to generate and distribute cash to shareholders, are likely to do well going forward.

#### ... that works in the current environment

Whilst the returns are not stellar, Free Cash Flow yield is still delivering returns for investors and importantly we believe will continue to do well. Based on our results, we suggest combining Free Cash Flow valuation models with a quality filter and a qualitative overlay to avoid value traps.

**Oliver Antrobus, CFA**

Analyst

oliver.antrobus@ubs.com

+61-3-9242 6467

**Paul Winter**

Analyst

paul-j.winter@ubs.com

+61-2-9324 2080

**Pieter Stoltz**

Analyst

pieter.stoltz@ubs.com

+61-2-9324 3779


**David Jessop**

Analyst

david.jessop@ubs.com

+44-20-7567 9882

**Figure 1: Value factors - rank correlation with subsequent returns (Asia ex Japan ex Financials, 12m horizon)**



Source: UBS Quantitative Database. A Rank IC > 0 indicates a positive relationship between valuation and future return at that point. The chart shows the 6-months rolling average IC through time to ease interpretation. The universe is DJ Asia ex Japan, ex Financials.

# Executive Summary

Many times in recent weeks conversations have turned to the subject of Value:

- What has happened to Value?
- Why isn't it working?
- When will it start working again?

These questions are of pivotal concern to quantitative investors, whose models almost always have some Value component – one of the oldest but perhaps still most confusing risk factors. In this note we review the recent performance of Value and consider why it seems to have stopped working, when it might return and whether all Value factors are affected equally.

Academic research tells us that investors preference is for simple valuation heuristics such as valuation multiples – these have performed very poorly in recent years. Whilst Value still has positive information content in Europe and Asia, the performance of Value factors is generally flat at best: Value still carries information, but it is a weaker driver of future returns than it has been over past years.

Our recent note on [Demographics](#) highlighted our view that growth rates are slowing. As a result we believe that wide spread upward re-ratings in valuation multiples due to higher earnings growth are less likely to occur. However, as we show in the report, the success of a Value strategy depends greatly on how the factor is defined – those of a defensive nature, that focus on the ability of firms to generate and distribute cash to shareholders, are likely to do well going forward.

Unlike the dividend discount model, which focuses on dividends to be paid, free cash flow is indicative of the *potential* to pay dividends. A free cash flow-based model allows us to remove the impact of accruals and estimate intrinsic value. The Free Cash Flow model is indicative of ability to pay dividends through a cycle more so than Dividend Yield.

Value's long-term outperformance is often criticised as a premium that can only be harvested effectively through small-cap stocks. We show that Value is still working – but its returns – as for those of the market – will be suppressed as investors get used to a world of demographically-driven lower growth rates and lower realised risk premia.

We show how DCF models are technically superior to single period models – capturing each company's growth profile as well as the risks around that growth. However we also remind readers that DCF models themselves are very sensitive to assumptions on terminal growth rates and discount rates, which require long term forecasts.

Given the heightened levels of macroeconomic risk at the current time it is therefore not surprising that investors are focussing on data that is nearer at hand. Free Cash Flow yield is a good combination of reported actual data, free of forecasting biases, with a cleaner numerator that has the desirable properties of being an indicator of future growth and dividend payments.

**Investors still prefer simple valuation heuristics such as earnings multiples**

**Slowing growth rates mean a rerating due to higher growth is unlikely**

**Defensive Value factors are those most likely to work...**

**... don't expect double digit returns going forward though**

**Free Cash Flow yield – and DCF models ...if you are confident about the assumptions**

# Introduction

When you ask an investor these days what they think about Value, the answer is a shrug of the shoulders. Isn't it all about Dividend Yield, Low Beta and Large Caps<sup>1</sup>? There are certainly sound reasons (see our Demographics note for more details) why these factors should continue to work strongly into the future.

Market thirst for income and defensive characteristics shows no signs of abating any time soon. What about other valuation signals? Is anything still working? Since the 2008 financial crisis you could be forgiven for thinking not – but all is not lost for Value investors. But when will that be? Market opinion is that this won't happen until "Growth" reappears – whenever that is. Certainly the performance of traditional Value signals has been pretty weak in the last year:

**Figure 2: Recent performance of traditional Value factors (excluding Financials)**

	Not Sector Neutral				Sector Neutral			
	BookYld	DivYld Fwd	Earn Yld Fwd	Intrinsic	BookYld	DivYld Fwd	Earn Yld Fwd	Intrinsic
Asia ex JP (all Caps)	-3.0%	-4.2%	-0.9%	2.2%	-0.8%	-6.7%	0.0%	0.0%
Asia ex JP (Large Caps)	3.5%	-7.8%	1.4%	4.9%	3.5%	-7.8%	1.4%	4.9%
Europe (all Caps)	-10.4%	-5.6%	-2.7%	-7.4%	-6.8%	-5.2%	0.3%	-4.6%
Europe (Large Caps)	1.1%	-5.9%	0.4%	3.7%	-6.9%	-2.9%	0.5%	-3.8%

Source: UBS Quantitative Database. Long-Short performance of Value in the 12 months to 30<sup>th</sup> November 2015.

Given that most valuation models use a similar combination of short-horizon factors – how do we do something slightly different, while keeping some sort of company-value anchor?

In this note we look at a number of Free Cashflow-based models, as well as doing some revision on when Value factors, and which, work through the cycle.

## Haven't we been here before?

There is international evidence for a persistent value premium (Fama and French, 1998). Our colleague Nick Baltas considered the arguments in our recent Academic Research Monitor looking at [Value Investing](#). Evidence tells us Value is either a compensation for risk or the result of a behavioural bias<sup>2</sup>.

Consider the following:

- Equity risk premia are at markedly different levels from those understood when much of the literature on Value was written; and

<sup>1</sup> Our monograph [Understanding Size Investing](#) discusses the connection between size returns and oligopolies, which is relevant to the "Dividend Yield outperforming" discussion.

<sup>2</sup> Our monograph [Understanding Value](#) discusses our views on the risk premia vs behavioural story.

- Have recent events – record low interest rates, demographics and yield demand, quantitative easing – changed those behavioural biases?

Even if the nature of Value has not fundamentally changed, it has certainly been affected by the above. Continued macro uncertainty flows onto uncertainty about growth – is there even any growth at all? The outlook for Growth cannot be separated from what is happening with Value. In particular the outlook for Cyclical Value, whose performance comes largely from earnings and multiple re-ratings at the start of an upturn, does not look promising at this stage.

In this note we look at recent history (using data since 2007). There is considerable literature on this subject but we aim to focus on how the factors are performing currently.

# Background and Literature Review

Not long after the dawn of fundamental analysis of the kind promoted by Graham and Dodd (1934), analysts started placing less emphasis on a company's asset base and increased their attention toward estimating a company's future earnings. Indeed, studies have found that stock price movements are more correlated with changes in earnings than other financial metrics including book value (Stickells, 1980; Black, 1980).

As equity markets became more sophisticated, sell side earnings estimates became a key piece of information by providing consensus expectations, which in turn allowed for the expression of anti-consensus expectations by individual brokers. I/B/E/S have compiled consensus earnings estimates since 1976 (though later for global markets) and professional investors have used these and individual broker estimates to inform valuation calculations – even by way of reference to the forward PE ratio – while making investment decisions ever since.

As equity markets continue to become more sophisticated, another shift in analyst focus is taking place. Earnings forecasts are coming under the microscope; firstly in regards to non-cash items or accruals, which can often distort a company's true earning power (Mohanram, 2014; Radhakrishnan and Wu, 2014). There is an increasing number of sell side analysts providing cash flow forecasts in addition to earnings forecasts (DeFond and Hung, 2003). Secondly, the market is becoming more interested in the appropriate risk premium to attach to those forecasts as evidenced by the rise in scenario based valuation (Joos, Piotroski and Srinivasan, 2012).

While sell side cash flow forecasts can be used to inform valuation calculations, the average broker and the average fund manager utilising broker estimates are yet to use them to their full potential. In their review of the literature, De Ricquebourg and Clacher (2015) found widespread evidence that, despite the rise in cash flow forecasts, both sell side and buy side analysts generally prefer unsophisticated valuation techniques and heuristics, such as price earnings multiples, when valuing stocks and making recommendations. They also found that these methods failed to earn U.S. investors excess returns from 2002 to 2012. Finally, they found that discounting methods were not often used.

Although cash flow forecasts may be underutilised, research suggests that they are likely to contain useful information. DeFond and Hung (2002) concluded that analyst cash flow estimates help market participants interpret the information contained in earnings, and to assess firm viability. Using I/B/E/S consensus data from 1993 to 2009, Jung (2015) found that when analysts issue cash flow forecasts the cost of capital decreases because analysts issue more accurate short-term and long-term earnings forecasts. He also found that the prevalence of cash flow forecasts reduced information asymmetry because of a negative association with the probability of informed trading.

There are also several other studies that comment on analyst cash flow forecasts in relation to accrual estimation. Call, Chen and Tong (2013) found that analyst cash flow forecasts outperform time series cash flow forecasts in predicting the sign and magnitude of the accruals. Gordon, Petruska and Yu (2014) also found that analyst cash flow forecasts attenuate overestimation of the accrual component of earnings. If cash flow forecasts hold valuable information then we are naturally interested in a valuation model that will harness their potential to earn excess returns.

**Academic research shows that simple valuation models such as earnings multiples are still preferred by investors**

De Ricquebourg and Clacher (2015) provided us with some insight in their recent study for the U.S. market. In addition to some other valuation models, the authors investigated a discounted cash flow model with five years' of consensus cash flow forecasts and a terminal value that assumes that cash flows fade from the final cash flow forecast to zero over a ten year period. Their model discounted cash flows by the industry cost of capital. Unlike the strategies based on heuristics or recommendations, they found that investors can earn excess returns by using consensus analysts' cash flow forecasts in a discounted valuation model. Size-adjusted excess returns for the discounted cash flow model were between 3.1% and 3.8%.

So far we have reviewed studies that support the use of cash flow forecasts. However, the literature is by no means unanimous on this point. Givoly, Hayn and Lehavy (2009) argue that analyst cash flow forecasts are a naïve extension of their earnings forecasts. Lehavy (2009), while supportive of the idea that cash flow forecasts improve the accuracy of earnings forecasts, showed that there was no improvement in accuracy in the six month period before an earnings release.

## Our hypothesis

We hypothesise that free cash flow data are valuable but that the extent to which they can be used to systematically generate excess returns will depend largely on the valuation framework that is applied.

In our report we use free cash flow available to equity holders as the basis for our discounted cash flow valuation models. UBS free cash flow available to equity holders is defined as follows:

**Free Cash Flow to Equity is the potential to pay dividends**

*Free cash flow available to equityholders*

*= Adjusted net income*

*+ Depreciation and amortisation*

*– Capital expenditure*

*– Increase in working capital*

Technically adjustments may be made for interest and tax accruals. However, we use the provided definition to avoid the complexity of manual adjustments. It should be noted that free cash flow estimates submitted for the calculation of consensus data may be defined differently by different brokers.

Free Cash Flow represents the cash a company generates from its ongoing operations, after taking into account the true costs of those operations. Free Cash Flow can either be returned to equity holders or reinvested in the business to drive future growth.

Unlike the dividend discount model, which focuses on dividends to be paid, free cash flow available to equity holders is indicative of the *potential* to pay dividends. While all accounting based valuation methods are equivalent given the same assumptions, discounted free cash flow available to equity holders valuation serves as a parsimonious framework to remove the impact of accruals on earning power and to estimate intrinsic value.

# Issues in Free Cash Flow Valuation

As with many things in life, there is an easy way and a hard way to do things.

Are single-period models the best way to look at Value? Seasoned stock analysts will argue "of course not". Growth companies look expensive and industries in structural decline look too cheap as every stock is forced onto the same growth profile.

With a cash flow model, there are several considerations:

- What is the horizon? Should we just use a single period? If so, should we look forward or backwards?
- What about more periods? The first year tells you only so much but ignores the growth. Where there is information about the future growth prospects we should use this.
- We use the Demographic implied growth rate to formulate our long-term growth assumptions.
- What is the terminal growth rate? Analyst long-term growth rate forecasts tend to be excessively optimistic – it is not uncommon to find perpetual growth rate forecasts of 10% or more in common use.
- What about the risk premium?<sup>3</sup>
- How do we form a sensible discount rate<sup>4</sup>? More specifically, how do we adjust for the riskiness of stocks – a single discount rate is too simplistic. We consider several approaches to adjusting the ex-ante risk premium, all of which start with Beta<sup>5</sup> as an initial indicator of a stock's systematic risk factor exposure.

---

<sup>3</sup> Forecasting the risk premium is a complex topic beyond the scope of this note!

<sup>4</sup> The discount rate to apply to the cash flow estimates can be broken into two parts. Firstly, the opportunity cost of funds or the time value of money must be considered and we use the 10 year government bond yield as a proxy for the risk free rate to discount this opportunity cost. Secondly, the risk premium to assign to the cash flows must be considered. The gold standard for discount rate and specifically risk premium attribution is the CAPM as defined by Sharpe (1964) and Lintner (1965). However, the CAPM has come under fire in recent years because it fails to produce empirical results that are consistent with theory. This inconsistency is best highlighted by the growing literature on the low beta or "betting against beta" phenomenon where low beta stocks tend to outperform high beta stocks. These observations run counter to the theory that more risky stocks with higher betas should compensate investors with higher returns, which have inspired some commentators to remark that "the CAPM is dead" (Fama and French, 1996).

<sup>5</sup> We use a 60 month rolling window for our stock betas, which are calculated by FactSet.

## How we tackled the problem

In this note we compare the results of four multi-stage discounted FCF models to current market price:

- A 5-year<sup>6</sup> discounted FCF model, using a discount rate of the forecast risk-free rate plus a risk premium adjusted by the stock's historic beta<sup>7</sup>,
- A 5-year discounted FCF model, using a discount rate of the forecast risk-free rate plus a risk premium adjusted using the process of Vasicek (this serves as a shrinkage estimator, see the appendix for more details),
- The model above but with no terminal phase, and
- A 5-year discounted FCF model, using a discount rate of the forecast risk-free rate plus a risk premium adjusted using a leverage-adjusted industry beta.

We use the difference between the 12-months forward earnings yield the bond yield as a proxy for the equity risk premium

We also look at some single-period models:

- 12 months' trailing Free Cash Flow yield (our data makes use of interim reporting periods and is from FactSet Fundamentals); and
- 12 months' forward, time-weighted Free Cash Flow yield (using consensus mean full-year forecasts from the I/B/E/S Summary Estimates data set);

4 multi-stage DCF models were looked at, alongside 2 simpler FCF yield models and several other "Value" factors

as well as some "traditional" value metrics:

- The last-reported Book Value to Price,
- The 12 months' forward (time weighted) consensus Earnings Yield,
- The 12 months' forward (time weighted) consensus Dividend Yield, and
- Our previously published "Intrinsic Value" which is a historic 3-year risk-adjusted cash flow model with a Book Value floor.

For our DCF models that use free cash flow forecasts, we used the mean summary estimate from the I/B/E/S estimates service. We time-weight the estimates, using a number of twelve-months-ahead periods rather than fiscal years such that the discounting is applied correctly. We did also consider using UBS' house forecasts however we have used consensus to be consistent with the other forward-looking factors<sup>8</sup>.

For our terminal growth rates, we refer to our published Demographic-implied growth rates (available annually on a per-country basis) for the year in which explicit cash flow forecasts end, adjusted by an inflation estimate<sup>9</sup>. As a sanity check to this, we also looked at the 10-year bond yield as a proxy for growth expectations (real growth expectations and inflation expectations). For this note, where the measurement period is very short and the demographic and inflation

Terminal growth: long term bond rate – or inflation adjusted demographic implied growth rate

---

<sup>6</sup> Where 3 or 4 years of forecasts are available instead of 5, we infer the future years' values using a terminal growth rate assumption.

<sup>7</sup> We use a 5-year monthly beta calculated relative to the local market, supplied by FactSet.

<sup>8</sup> I/B/E/S definition of Operating Cash Flow considers a company's net cash position over a given period, i.e. money received from customers minus taxes, interest payments, dividend payments and payments to suppliers. Free Cash Flow deducts maintenance capex from this number.

<sup>9</sup> We used a constant 2% inflation rate forecast – central bank models often use a rate in the 2-3% range. For a longer period or different inflation environment the Bond Yield is an alternative approach.



rates benign and relatively stable we consider this adequate – for a longer study we would need to consider this more thoroughly.

Our measurement period begins at the end of 2007, and portfolios are rebalanced monthly where appropriate. We recognise that Value signals tend to move slowly – as such the turnover is quite low. A longer rebalance horizon would flatter the absolute performance of all these factors however it would not dramatically affect the results of this study.

We look separately at performance within Europe and Asia (ex Japan), using the Dow Jones indices. To address the concerns that this may introduce a small-cap tilt to the results, we also repeat the analysis within the larger and more liquid equivalent MSCI universes, and report these results where appropriate.

We exclude Financials from all these models – and the benchmarks they are measured against, in the absence of any agreement on what constitutes free cash flow, for example, for a Bank. For Europe we measure all returns in Euros and for Asia in US Dollars.

**We exclude Financials. What is the Free Cash Flow for a bank?**

## **What does a multi-period Free Cash Flow model look like?**

In our initial data set we observed that the various DCF models agreed much more on the stocks the models considered were overvalued than those that considered undervalued. We attribute this to the significant differences between the DCF models being towards the terminal growth phase, with the nearer, less-discounted cash flows being treated relatively similarly.

**The various models agree more on which stocks are "expensive" than on undervalued stocks.**

For those stocks deemed extremely overvalued by the models, the price level on the denominator far outweighs the importance of the intrinsic value on the numerator. However, for those stocks deemed undervalued by the models, the way that intrinsic value on the numerator is defined becomes much more important; each model tells a slightly different story. As a consequence we observe consensus among the models when it comes to identifying extremely overvalued companies and a lack of consensus among the models when it comes to identifying undervalued companies.

In unreported results we also looked at the same models with a three-year discount phase rather than five years, again the results were similar (see below where we discuss the weight of the Terminal Value).

## **Does using free cash flow forecasts create a bias?**

In our initial sample of data we found that 12% of stocks were "overvalued" (a DCF valuation less than the current market value), 43% of stocks were broadly fairly valued (a V/P ratio of between 1 and 2) and 45% of stocks were undervalued (a V/P ratio of greater than 2), suggesting that DCF models of this nature tend to overvalue companies relative to the market's "real" valuation<sup>10</sup>. Nonetheless in our opinion this presents no issue when comparing companies in a ranking (relative) sense. For this reason we also keep companies with a negative V/P ratio.

Certainly forecasting free cash flows requires some significant resource to model, and thus these forecasts are generally available more for larger stocks; however

---

<sup>10</sup> These statistics are measured over the whole time period – at any point in time the proportion that are over- or under-valued could be markedly different given the use of market beta to adjust the ERP.

these estimates cover the large majority of the universe of stocks we have used for this report.

The literature on free cash flow forecasts doesn't really acknowledge these tilts except implicitly comparing size adjusted returns.

We should note that Value generally offers a small low-beta bias. Our value portfolios (discussed later) generally had a long-side beta of around 0.90 and a short-side beta of around 1.05.

## **How much of the DCF valuation is represented by the terminal value?**

Across all the DCF models we have proposed, across sectors and through the history from 2007, the proportion of the DCF valuation that is represented by the terminal value is consistently in the 70-80% range.

**Terminal Value generally represents 70-80% of DCF valuation across these models**

Interest rates have fallen to historic lows during the period of this paper (and were relatively low by historic standards to start with) – clearly lower interest rates imply that the Terminal Value will be larger proportion of the valuation.

One important strength of multi-period valuation models is capitalising forecasts beyond the first year. Capitalising later forecasts to a greater extent than near-term forecasts (especially if they are higher than 1 year forecasts) could mean the model is capable of identifying growth names more effectively.

The emphasis on Terminal Value will remain high as long as rates stay low. The implication is that yard sticks like 12 months' forward PE ratios will be even less relevant than in the past if rates stay low.

# Results

We first assess our Value metrics using Information Coefficients – the rank correlation between scores and subsequent returns, over a 1-, 3- and 12-month horizon. The IC allows evaluation of the information content of the signal independent of portfolio construction mechanism. Noting the cyclicity of the IC we pay attention to both a time series plot and summary data.


The chart below shows the 12m horizon IC of the various value factors we looked at, for the Asia-ex-Japan constituents of the Dow Jones indices. You see similar results in Europe and also within larger caps (See Appendix B for full details).

Some difference in the results between Asia and Europe is of course expected. The latter is a more mature market, without the weight in EM, a different growth and inflation profile and possibly different investor preferences and attitudes, in part led by differing demographics.

Several things immediately stand out:

- Not all value factors appear to have information at the same time. At times there is significant dispersion (and at times very little).
- Dividend Yield, long the king of the Value factors, appears to have returned to the pack;
- Trailing Free Cash Flow yield is consistently positive, and has had the highest current IC and the highest risk-adjusted IC.

**Figure 3: Value factors - rank correlation with subsequent returns (Asia ex Japan ex Financials, 12m horizon)**



Source: UBS Quantitative Database. A Rank IC > 0 indicates a positive relationship between valuation and future return at that point. The chart shows the 6-months rolling average IC through time to ease interpretation. The universe is DJ Asia ex Japan, ex Financials.

The DCF valuation models all had similar results – it seems to a certain extent the various discount rate scenarios are picking up on the same effect.

Within Asia, absolute ICs have been low in the last two years compared to recent history, and we see the same within large caps, though trailing Free Cash Flow yield still remains positive. Appendix B shows these results in detail. In Europe the ICs of most Value factors are flat at best, even within a broad universe.

The results within sector require some interpretation – for example, in the Energy sector, Dividend Yield tends to favour producers rather than explorers, the latter of which tend to have no dividends or earnings, or Telecoms where you tend to have a polarity of large incumbents (which often offer a relatively high yield) vs smaller incumbents whose Value may be in the out-years.

**Figure 4: IR (Rank IC scaled by volatility) within GICS sector – Asia ex Japan**

	Cons Disc	Cons Stpls	Energy	Healthcare	Industrials	Info Tech	Materials	Telecoms	Utilities
DCF (Adj Beta)	0.71	0.47	0.36	0.16	0.11	0.32	0.14	-0.06	0.33
BookYld	0.43	-0.35	0.35	0.51	0.42	0.21	1.26	-0.50	0.20
DivYld Fw d	0.62	0.83	0.89	1.05	1.77	1.69	1.55	0.85	0.87
EarnYld Fw d	0.80	0.06	0.83	0.76	1.81	1.57	0.82	0.61	0.49
FCFY Trl	1.20	0.87	0.74	0.56	1.53	2.15	1.14	1.05	1.23
Intrinsic	0.63	-0.09	1.19	0.56	1.24	0.26	1.52	-0.63	0.82
DCF (Lev Adj Ind Beta)	0.33	0.32	0.36	0.17	0.31	0.06	-0.16	-0.04	0.39
DCF (no TV)	0.32	0.22	0.20	0.17	0.05	0.26	-0.08	-0.15	0.45
FCFY Fw d	0.34	0.68	0.25	0.13	0.00	0.83	0.40	0.08	0.49
DCF (Vasicek Adj)	0.52	0.26	0.30	0.07	0.07	0.21	0.03	0.16	0.32

Source: UBS Quantitative Database. Measured from December 2007 to January 2015. Annualised IC is scaled by the volatility of the IC over the period.

We know from our literature review that the market pays a lot of attention to near-term, conventional value metrics in the short term. The period tested has been characterised by low interest rates and less dispersed betas so the discount rate has been less important, so the current environment may be masking the true potential of the DCF models.

Models that make use of forecast data also have more room for error, or mis-estimation. This doesn't mean that DCF models should be overlooked but it does remind us of their sensitivity to the inputs used – the transfer of their technical superiority comes down to how they are used in practice.

## Factor Score correlations

Before we conduct any further analysis we need to make sure our newly proposed models aren't telling us something else by loading up on factors we already know about – we look at the average rank correlation to assess this. These results are for Asia; the results for Europe are similar.

**Figure 5: Correlation between yield and other selected factors – Asia ex Japan**

	Beta	BookYld	Delta Quality	DivYld Fw d	EarnYld Fw d	FCFY Trl	High Quality	Intrinsic	Size
DCF (Adj Beta)	-0.236	0.072	0.098	0.262	0.190	0.239	0.152	0.186	-0.012
DCF (Lev Adj Ind Beta)	-0.054	0.081	0.099	0.233	0.211	0.260	0.165	0.164	-0.034
DCF (no TV)	0.032	0.157	0.042	0.217	0.240	0.229	0.056	0.208	-0.067
FCFY Fw d	-0.030	0.069	0.101	0.284	0.241	0.310	0.128	0.137	-0.064
DCF (Vasicek Adj)	-0.048	0.116	0.061	0.213	0.202	0.208	0.076	0.177	-0.047

Source: UBS Quantitative Database. Measured from December 2007 to January 2015. Universe is DJ Asia ex Japan, ex Financials.

Unsurprisingly there is a strong correlation between all the proposed models and FCF Yield, and also with Dividend Yield and Quality, which is promising, both in terms of picking a defensive value factor, and something that works. We do note a consistent size (small cap) bias, something which is commonly seen in the literature on Value.

From an analytical standpoint, we suggest that cash flow forecasts are more likely to be overly optimistic in smaller companies, especially with regards to future growth rate assumptions. One might expect a larger range of possible cash flow outcomes for smaller companies given where they are in their lifecycle - given that larger range, optimism bias will be more pronounced for those companies.


## Cross-sectional Value deciles

We look at the annualised average excess returns of our Value factors, broken into (sector-neutral) deciles. Whilst not monotonic, we observe the general, and expected pattern that cheaper stocks are still outperforming expensive stocks since 2007, though. This gives us confidence that Value, and specifically defensive Value factors, are still working.

Each of these charts is of the risk-adjusted return (Sharpe ratio – annualised excess return scaled by annualised standard deviation of return).

**Book Yield and 12-months-forward Free Cash-Flow Yield are the least consistent**

**Figure 6: Decile Risk-Adjusted Returns - Asia-ex-Japan (excluding Financials) - All Caps**




Source: UBS Quantitative Database. Data is for Asia-ex-Japan since December 2007. Average annualised risk-adjusted returns are broken out by sector-neutral Value decile.

We observe that Decile 1 (the most expensive stocks) doesn't behave as it "should", though this is a pattern we often see when looking at extremes of Value, we attribute this to being stocks where the value metric or level is irrelevant or discounted by the market.

But what about large caps? In the larger-cap stocks within Asia-ex-Japan, the results are much the same:


**Figure 7: Decile Risk-Adjusted Returns – Asia-ex-Japan (excluding Financials) - Large Caps**



Source: UBS Quantitative Database. Data is for Asia-ex-Japan since December 2007. Large Cap stocks are proxied by the MSCI AC Asia ex Japan (excluding Financials) universe. Average annualised risk-adjusted returns are broken out by sector-neutral Value decile.

For Large Caps in Europe the results are a little more mixed: it appears that Value works better in selecting expensive stocks at the moment, though we note that trailing Free Cash Flow Yield is again working effectively:

**Figure 8: Decile Risk-Adjusted Returns – European large caps (excluding Financials)**



Source: UBS Quantitative Database. Data is for Europe since December 2007. Large Cap stocks are proxied by the MSCI Europe (ex Financials) universe. Average annualised risk-adjusted returns are broken out by sector-neutral Value decile.

The pronounced returns in the tails could have implications for the optimum weight for value strategies, as well as reminding us of the importance of addressing extremes when creating Value portfolios. In our note [Lessons from Behavioural Finance](#) we discuss the importance of aligning our weights with our highest convictions.

## Portfolio Simulations

We perform some basic portfolio simulations to get a feel for the returns from investing in the factors that we discuss above. Portfolio construction of Value factors is a complex area and we make a number of significant simplifying assumptions. Our intention is not to describe investable portfolios but to give an indication of factor performance in recent times.

- We split the universe (ex-Financials) into thirds and measure the performance of "Cheap minus Expensive"
- We use sector-neutral versions of each Value factor.
- We use cap-weighted portfolios to avoid concerns with liquidity<sup>11</sup>. To achieve sector neutrality with cap weighted portfolios we reweight the stocks such that the sector weights are in line with the universe sector weight (e.g. if Utilities are 15% of the universe then the "Cheap" third will have 15% by weight in Utilities. We report the cap-weighted results in this note (equally weighted results available on request).
- We resample the portfolio monthly and returns are free of transaction costs (we note that Value factors generally have low turnover).
- We scale each portfolio such that it has an ex-ante Beta of 1.

### Sector-Neutral Value: Cap-Weighted Thirds

In Appendix C we present the time series of 12 month rolling returns. Statistical measures over the period somewhat flatter the returns due to the strong performance of Value early in the period.

**Figure 9: Last 12 months' return to Value (Sector Neutral)**

	DCF (Adj Beta)	BookYld	DivYld Fwd	Earn Yld Fwd	FCFY Trl	Intrinsic	DCF (Lev Adj Ind Beta)	DCF (no TV)	FCFY Fwd	DCF (Vasicek Adj)
Asia ex JP (all Caps)	-0.5%	-0.8%	-6.7%	0.0%	-5.8%	0.0%	-6.1%	-5.9%	-1.5%	-3.8%
Asia ex JP (Large Caps)	-5.2%	3.5%	-7.8%	1.4%	-4.7%	4.9%	0.5%	-1.3%	1.0%	3.9%
Europe (all Caps)	-4.3%	-6.8%	-5.2%	0.3%	-0.1%	-4.6%	-7.2%	-5.8%	-6.9%	-6.3%
Europe (Large Caps)	-4.4%	-6.9%	-2.9%	0.5%	2.4%	-3.8%	-6.9%	-3.8%	-6.6%	-4.1%

Source: UBS Quantitative Database. Results exclude Financials. 12 months to 30 November 2015. For details on the construction mechanism please refer to the above commentary.

12-month rolling returns in Asia have faded to slightly negative for most factors in the last two years, and we see similar, though less amplified results in large caps. In Europe Value has generally not produced significant returns since the financial crisis, though it seems actual (as opposed to forecast) Free Cash Flow is still being rewarded.

<sup>11</sup> The results with equally-weighted portfolios followed a similar pattern though the absolute magnitude of the results was higher.

The returns to Value tend to come from different "sides" of the Value spectrum. In bull markets <sup>12</sup> expensive stocks tend to perform in line with the market whilst cheap stocks outperform – in bear markets the opposite tends to be true.

Without controlling for sectors one can see evidence that Value has been working somewhat better when allowed to pick sectors, although the results are far from consistently positive.

**Figure 10: Last 12 months' return to Value (not Sector Neutral)**


	DCF (Adj Beta)	BookYld	DivYld Fwd	Earn Yld Fwd	FCFY Trl	Intrinsic	DCF (Lev Adj Ind Beta)	DCF (no TV)	FCFY Fwd	DCF (Vasicek Adj)
Asia ex JP (all Caps)	0.3%	-3.0%	-4.2%	-0.9%	-4.8%	2.2%	-2.3%	-2.9%	-0.4%	0.4%
Asia ex JP (Large Caps)	-5.2%	3.5%	-7.8%	1.4%	-4.7%	4.9%	0.5%	-1.3%	1.0%	3.9%
Europe (all Caps)	-4.1%	-10.4%	-5.6%	-2.7%	2.8%	-7.4%	-3.8%	-5.4%	-5.1%	-1.2%
Europe (Large Caps)	4.3%	1.1%	-5.9%	0.4%	-5.6%	3.7%	0.3%	-1.5%	2.2%	4.5%

Source: UBS Quantitative Database. Results exclude Financials. 12 months to 30 November 2015. For details on the construction mechanism please refer to the above commentary.

**We should of course be careful not to extrapolate too much from a backtest with such a short window and a unique set of economic conditions – even within which the performance of Value is far from constant.**

We report summary statistics at Appendix D.

**Figure 11: Risk-adjusted return (Sharpe ratio) of various Value factors since 2007 (Asia ex Japan)**



Source: UBS Quantitative Database. Annualised return divided by annualised standard deviation of returns from December 2007 to November 2015. Universe is DJ Asia ex Japan (excluding Financials).

<sup>12</sup> Our [Investing in Value](#) note discussed this in more detail



## The intersection of Value and Quality is still the place you want to be

We looked at our preferred combination of Value and Change in Quality: in our previous publication [Investing in Value](#) we have seen that the intersection of Increasing Quality and Value was the best combination; here we look at 3 of the Value metrics we discuss in this note, and pleasingly we note similar patterns using this recent data.

**Figure 12: Average annualised excess returns, Quality/Value intersection, Asia ex Japan**

		Value Decile (10: Most Preferred)									
Model	Change in Quality	1	2	3	4	5	6	7	8	9	10
DCF (Vasicek Beta Adj)	Decreasing	6.0%	-13.5%	-10.3%	-15.7%	-24.3%	-19.4%	-16.2%	9.4%	11.5%	-1.6%
	Stable	1.2%	-12.7%	-1.3%	-1.0%	1.7%	-0.5%	-1.4%	-1.7%	-5.2%	2.8%
	Increasing	-3.6%	-6.2%	1.3%	8.5%	3.7%	5.8%	5.6%	8.8%	4.7%	17.7%
Trailing FCF Yield	Decreasing	-6.3%	-10.3%	-10.6%	-4.6%	-12.8%	-10.9%	-7.1%	-0.1%	0.5%	-3.8%
	Stable	1.4%	-3.5%	-4.1%	-3.6%	-0.4%	2.2%	0.7%	2.6%	2.4%	8.2%
	Increasing	2.0%	-4.0%	4.1%	7.5%	8.4%	6.0%	6.5%	10.4%	11.7%	15.1%
Dividend Yield (fwd)	Decreasing	-8.0%	-13.9%	-15.3%	-15.5%	-3.7%	-4.6%	0.5%	-4.9%	3.8%	10.9%
	Stable	-3.1%	-2.5%	-2.5%	2.6%	-3.6%	1.0%	0.9%	4.7%	2.1%	4.5%
	Increasing	16.7%	0.6%	14.0%	6.6%	6.9%	10.1%	7.3%	10.6%	11.9%	13.1%

Source: UBS Quantitative Database. Measured from December 2007 to January 2015. The numbers displayed are the average annualised excess return, cross-sectionally, for that combination of Quality and Value. Universe is DJ Asia ex Japan, excluding Financials.

These results are for Asia ex Japan, we see similar results in Europe, and in large caps (in both Europe and Asia).


## Isn't it getting a bit crowded in here?

To some extent FCF yield – be it short term or discounted longer-term – is a proxy for what is working (what the market wants) – growth potential and visible cash flows – and that is no bad thing.

As a result of this, particularly in the recent year as the effectiveness of the dividend yield strategy has declined somewhat, there is the potential for high Free Cash Flow Yield to become crowded as investors search for alternatives.

These charts show our Style Crowdedness Indicator for Asia-ex-Japan and Europe for a number of factors and we note that this is indeed the case:


**Figure 13: Style Crowdedness Indicators for Asia-ex-Japan**



Source: UBS Quantitative Database. MSCI AC Asia ex Japan universe.

And similar results within Europe:

**Figure 14: Style Crowdedness Indicators for Europe**



Source: UBS Quantitative Database. MSCI Europe universe.

We note that Value styles in particular can remain 'crowded' for some time. Our research on crowded trades suggests keeping an eye on stock-level absolute valuation and sentiment (e.g. via earnings revisions or price momentum) as a way to avoid mean-reversion of crowded trades.

## What does the relative performance of the DCF models tell us?

Our hypothesis was that analyst cash flow estimates have value but need to be used in the right framework to earn excess returns – our brief analysis tells us that that framework is not an easy thing to specify. We suggest a few reasons why near-term estimates have strong predictive power:

**DCF models are very sensitive to the assumptions used**

- Trailing free cash flow numbers, using quarterly or semi-annual data, give us our most accurate view into what is going on in the company – the regularity of updates (compared to annual forecasts) act to reduce risk;
- There are a lot of moving parts in any terminal growth rate assumption – it is hard enough to forecast the next period let alone something five years out – and macroeconomic factors – direction and level of interest rates, FX, and inflation, are all of heightened and primary concern at the moment;
- These same factors introduce significant uncertainty into what the appropriate discount rate to be used for future cash flows is;
- Analysts (and the market that prices these factors) are almost certainly using higher terminal growth rates than the demographics imply, e.g. for much of Europe the Demographics-implied growth rate has turned negative – our view is that the market has yet to fully price these in.

Only time will tell whether our assumptions are anything near valid - given all this uncertainty, it is perhaps not surprising that investors appear to be placing more reliance on models with near-term estimates given the uncertain future outlook.

**What assumptions the market is using, or implying?**

## Why does Book Value look so bad?

One consistent theme through all our results is that Book Value has performed very poorly throughout the period – at its best it has performed in line with other Value factors and at times has significantly underperformed. In our recent paper on [Investing in Value](#) we categorised Value factors broadly as follows:

- Book Value – compensation for distress risk
- Earnings Yield – cyclical value
- Dividend Yield (and Cash Flow) – defensive value

As we discussed in this note, the combination of quantitative easing and record low interest rates has upset the risk-reward balance to some extent – indeed highly-leveraged asset-light companies have performed strongly in recent years.

# Conclusions

Academic research tells us that investors preference is for simple valuation heuristics such as valuation multiples – these have performed very poorly in recent years.

In this paper we outline how Free Cash Flow can be considered the *potential* to pay dividends or return capital to investors, or to be reinvested for future growth, and we introduced and reviewed models that make use of Free Cash Flow in a valuation framework to form a superior valuation factor.

Demographics will be a driver of lower growth rates into the future. In this environment investors are likely to continue to favour Defensive Value - companies with the ability to generate cash and pay dividends at a reasonable valuation. These factors tend to have lower beta and volatility as a side-effect – which is no bad thing in the current environment.

We show how DCF models are technically superior to single period models – capturing each company's growth profile as well as the risks around that growth. However we also remind readers that DCF models themselves are very sensitive to assumptions on terminal growth rates and discount rates, which require long term forecasts.

Given the heightened levels of macroeconomic risk at the current time it is therefore not surprising that investors are focussing on data that is nearer at hand. Free Cash Flow yield is a good combination of reported actual data, free of any forecasting biases, with a cleaner numerator that has the desirable properties of being an indicator of future growth and dividend payments.

## How to invest in Free Cash Flow Yield

We recommend combining Free Cash Flow valuation with Quality and a qualitative overlay to avoid value traps. In our stock lists we first start by avoiding low quality (both low absolute quality and declining quality). We listen to the market by excluding stocks on our "Bear Ideas" screen and those that carry a "Sell" rating from UBS analysts, and then look for the best Free Cash Flow Yield opportunities within each sector.

**Free Cash Flow yield – and DCF models ...if you are confident about the assumptions**

# Stock lists

In each region we select stocks that were Neutral or High in terms of our High Quality Model, Stable or Improving in terms of our Delta Quality model, are not flagged by our "Bear Ideas" model, and do not carry a "Sell" rating from UBS' fundamental analysts. We then select the two stocks with the highest trailing free cash flow yield in each sector (excluding Financials).

**Figure 15: Europe (MSCI Europe, excluding Financials)**

Industry Group	Security Name	Symbol	Country	Trailing FCF Yield	Recommendation	Price Target	PT Currency
Consumer Discretionary	PEUGEOT SA	UG.FP	FR	76.2%	Neutral	16	EUR
Consumer Discretionary	PROSIEBENSAT.1 MEDIA SE	PSM.GY	DE	14.3%			
Consumer Staples	HEINEKEN HOLDING NV	HEIO.NA	NL	7.5%			
Consumer Staples	KONINKLIJKE AHOLD NV	AH.NA	NL	7.5%	Neutral	18.5	EUR
Energy	TENARIS SA	TEN.IM	IT	8.6%	Buy	29	USD
Energy	ENI SPA	ENI.IM	IT	6.8%	Buy	17	EUR
Health Care	SHIRE PLC	SHP.LN	GB	9.4%	Buy	62	GBP
Health Care	SANOFI	SAN.FP	FR	6.3%	Neutral	90	EUR
Industrials	BOSKALIS WESTMINSTER	BOKA.NA	NL	11.8%			
Industrials	PRYSMIAN SPA	PRY.IM	IT	10.5%			
Information Technology	HEXAGON AB-B SHS	HEXAB.SS	SE	5.9%	Buy	333	SEK
Information Technology	AMADEUS IT HOLDING SA-A SHS	AMS.SQ	ES	5.7%	Neutral	44	EUR
Materials	NORSK HYDRO ASA	NHY.NO	NO	14.9%	Neutral	32	NOK
Materials	BOLIDEN AB	BOL.SS	SE	9.3%	Buy	160	SEK
Telecommunication Services	TDC A/S	TDC.DC	DK	13.5%	Neutral	39	DKK
Telecommunication Services	ORANGE	ORA.FP	FR	11.2%	Neutral	15.9	EUR
Utilities	GAS NATURAL SDG SA	GAS.SQ	ES	13.1%	Neutral	19	EUR
Utilities	ENDESA SA	ELE.SQ	ES	10.5%	Neutral	20	EUR

Source: UBS Quantitative Database

**Figure 16: Asia ex Japan (MSCI AC Asia ex Japan, excluding Financials)**

Industry Group	Security Name	Symbol	Country	Trailing FCF Yield	Recommendation	Price Target	PT Currency
Consumer Discretionary	DONGFENG MOTOR GRP CO LTD-H	489.HK	CN	17.2%	Buy	12.5	HKD
Consumer Discretionary	JARDINE CYCLE & CARRIAGE LTD	JCNC.SP	SG	17.1%			
Consumer Staples	THAI UNION GROUP PCL	TU.TB	TH	13.1%	Buy	24.5	THB
Consumer Staples	WILMAR INTERNATIONAL LTD	WIL.SP	SG	12.3%			
Energy	SK INNOVATION CO LTD	096770.KP	KR	26.8%			
Energy	PTT EXPLOR & PROD PUBLIC CO	PTTEP.TB	TH	23.4%	Buy	93	THB
Health Care	SINO BIOPHARMACEUTICAL	1177.HK	CN	4.6%	Neutral	6.9	HKD
Health Care	DR. REDDY'S LABORATORIES	DRRD.IS	IN	2.9%	Neutral	4750	INR
Industrials	AIR CHINA LTD-H	753.HK	CN	31.7%	Buy	7	HKD
Industrials	HYUNDAI DEVELOPMENT CO-ENGIN	012630.KP	KR	29.1%	Neutral	46500	KRW
Information Technology	INNOLUX CORP	3481.TT	TW	82.8%	Neutral	11	TWD
Information Technology	INOTERA MEMORIES INC	3474.TT	TW	16.8%	Neutral	30	TWD
Materials	TAIWAN FERTILIZER CO LTD	1722.TT	TW	44.1%			
Materials	POSCO	005490.KP	KR	27.1%	Buy	215000	KRW
Telecommunication Services	PCCW LTD	8.HK	HK	31.1%			
Telecommunication Services	KT CORP	030200.KP	KR	17.8%	Neutral	34000	KRW
Utilities	HUANENG POWER INTL INC-H	902.HK	CN	25.8%	Neutral	7.2	HKD
Utilities	GLOW ENERGY PCL	GLOW.TB	TH	14.4%	Buy	97	THB

Source: UBS Quantitative Database

**Figure 17: North America (MSCI North America, excluding Financials)**

Industry Group	Security Name	Symbol	Country	Trailing FCF Yield	Recommendation	Price Target	PT Currency
Consumer Discretionary	GAMESTOP CORP-CLASS A	GME.UN	US	18.3%			
Consumer Discretionary	SCRIPPS NETWORKS INTER-CL A	SNI.UN	US	11.3%	Neutral	60	USD
Consumer Staples	WESTON (GEORGE) LTD	WN.CT	CA	11.1%			
Consumer Staples	WAL-MART STORES INC	WMT.UN	US	7.4%	Neutral	64	USD
Energy	VALERO ENERGY CORP	VLO.UN	US	12.1%			
Energy	TESORO CORP	TSO.UN	US	9.1%			
Health Care	AMERISOURCEBERGEN CORP	ABC.UN	US	13.5%	Buy	122	USD
Health Care	GILEAD SCIENCES INC	GILD.UW	US	11.7%	Buy	138	USD
Industrials	ADT CORP/THE	ADT.UN	US	13.0%			
Industrials	DELTA AIR LINES INC	DAL.UN	US	10.5%	Buy	64	USD
Information Technology	APPLE INC	AAPL.UW	US	11.5%	Buy	130	USD
Information Technology	EBAY INC	EBAY.UW	US	11.1%	Buy	34	USD
Materials	NUCOR CORP	NUE.UN	US	13.8%	Buy	47	USD
Materials	TURQUOISE HILL RESOURCES LTD	TRQ.CT	CA	13.4%			
Telecommunication Services	CENTURYLINK INC	CTL.UN	US	16.0%	Buy	36	USD
Telecommunication Services	VERIZON COMMUNICATIONS INC	VZ.UN	US	10.0%	Neutral	48	USD
Utilities	OGE ENERGY CORP	OGE.UN	US	6.8%			
Utilities	PUBLIC SERVICE ENTERPRISE GP	PEG.UN	US	3.1%	Neutral	42	USD

Source: UBS Quantitative Database

**Figure 18: Japan (Topix 500, excluding Financials)**

Industry Group	Security Name	Symbol	Country	Trailing FCF Yield	Recommendation	Price Target	PT Currency
Consumer Discretionary	IIDA GROUP HOLDINGS CO LTD	3291.JT	JP	18.7%			
Consumer Discretionary	HONDA MOTOR CO LTD	7267.JT	JP	16.7%	Neutral	4000	JPY
Consumer Staples	LAWSON INC	2651.JT	JP	7.1%			
Consumer Staples	SUGI HOLDINGS CO LTD	7649.JT	JP	6.0%			
Energy	JAPAN PETROLEUM EXPLORATION	1662.JT	JP	2.2%			
Health Care	TOHO HOLDINGS CO LTD	8129.JT	JP	11.6%			
Health Care	NICHI-IKO PHARMACEUTICAL CO	4541.JT	JP	10.1%			
Industrials	SANKYU INC	9065.JT	JP	17.0%			
Industrials	IWATANI CORP	8088.JT	JP	16.7%			
Information Technology	RYOSAN CO LTD	8140.JT	JP	11.9%			
Information Technology	RICOH CO LTD	7752.JT	JP	11.4%			
Materials	MITSUBISHI GAS CHEMICAL CO	4182.JT	JP	19.1%			
Materials	MITSUBISHI CHEMICAL HOLDINGS	4188.JT	JP	18.1%	Neutral	780	JPY
Telecommunication Services	NIPPON TELEGRAPH & TELEPHONE	9432.JT	JP	11.8%	Buy	5400	JPY
Telecommunication Services	NTT DOCOMO INC	9437.JT	JP	6.5%	Neutral	2300	JPY
Utilities	CHUBU ELECTRIC POWER CO INC	9502.JT	JP	17.2%			
Utilities	TOHO GAS CO LTD	9533.JT	JP	6.1%			

Source: UBS Quantitative Database

**Figure 19: Australia (S&P/ASX 200, excluding Financials)**

Industry Group	Security Name	Symbol	Country	Trailing FCF Yield	Recommendation	Price Target	PT Currency
Consumer Discretionary	NINE ENTERTAINMENT CO HOLDIN	NEC.AT	AU	12.3%	Buy	1.65	AUD
Consumer Discretionary	SKY NETWORK TELEVISION LTD	SKT.AT	AU	9.4%	Neutral	4.9	NZD
Consumer Staples	COCA-COLA AMATIL LTD	CCL.AT	AU	3.8%	Neutral	9.35	AUD
Consumer Staples	WESFARMERS LTD	WES.AT	AU	3.8%	Neutral	41.5	AUD
Energy	WOODSIDE PETROLEUM LTD	WPL.AT	AU	13.6%	Neutral	33.1	AUD
Energy	OIL SEARCH LTD	OSH.AT	AU	6.4%	Neutral	7.65	AUD
Health Care	ESTIA HEALTH LTD	EHE.AT	AU	8.4%	Buy	9.1	AUD
Health Care	RESMED INC-CDI	RMD.AT	AU	4.4%	Buy	70	USD
Industrials	DOWNER EDI LTD	DOW.AT	AU	18.3%			
Industrials	PROGRAMMED MAINTENANCE SERV	PRG.AT	AU	11.9%	Buy	3.15	AUD
Information Technology	IRESS LTD	IRE.AT	AU	4.7%			
Information Technology	ALTium LTD	ALU.AT	AU	4.0%			
Materials	PACT GROUP HOLDINGS LTD	PGH.AT	AU	14.0%	Neutral	4.2	AUD
Materials	NORTHERN STAR RESOURCES LTD	NST.AT	AU	12.7%			
Telecommunication Services	M2 GROUP LTD	MTU.AT	AU	5.0%	Neutral	9.4	AUD
Telecommunication Services	TPG TELECOM LTD	TPM.AT	AU	3.0%			
Utilities	AGL ENERGY LTD	AGL.AT	AU	2.2%	Neutral	16.5	AUD

Source: UBS Quantitative Database

# Bibliography

[Baltas, M. et al \(2015\). Value Investing. UBS Academic Research Monitor.](#)

Black, F. (1980). The magic in earnings: Economic earnings versus accounting earnings. *Financial Analysts Journal*, 36(6), 19-24.

Call, A., Chen, S. and Tong, Y., 2009. Are Analysts' Earnings Forecasts More Accurate When Accompanied by Cash Flow Forecasts? *Review of Accounting Studies*, 14, 358-391.

Defond, M. and Hung, M., 2003. An Empirical Analysis of Analysts' Cash Flow Forecasts. *Journal of Accounting and Economics*, 35, 73-100.

de Ricquebourg, D., Alan, J., & Clacher, I. (2015). Evidence on Analyst Stock Recommendations, Cash Flow Valuations, and Stock Return Profitability. *Cash Flow Valuations, and Stock Return Profitability* (September 7, 2015).

Fama, E. F., & French, K. R. (1996). The CAPM is wanted, dead or alive. *The Journal of Finance*, 51(5), 1947-1958.

Gordon, E. A., Petruska, K. A., & Yu, M. (2014). Do Analysts' Cash Flow Forecasts Mitigate the Accrual Anomaly? International Evidence. *Journal of International Accounting Research*, 13(1), 61-90.

Givoly, D., Hayn, C. and Lehavy, R., 2009. The Quality of Analysts' Cash Flow Forecasts. *The Accounting Review*, 84, 1877–1911.

Graham, B., Dodd, D. L. F., & Cottle, S. (1934). *Security analysis* (pp. 44-45). New York: McGraw-Hill.

Joos, P. R., Piotroski, J. D., & Srinivasan, S., 2012. Can analysts assess fundamental risk and valuation uncertainty? An empirical analysis of scenario-based value estimates.

Jung, S. H., 2015. Are analysts' cash flow forecasts useful? *Wiley Online Library*.

Lehavy, R., 2009. Are Earnings Forecasts More Accurate When Accompanied by Cash Flow Forecasts? *Review of Accounting Studies*, 14, 392-400.

Mohanram, P.S., 2014. Analysts' Cash Flow Forecasts and the Decline of the Accruals Anomaly. *Contemporary Accounting Research*, 31, 1143-1170.

Radhakrishnan, S. and Wu, S.-L., 2014. Analysts' Cash Flow Forecasts and Accrual Mispricing. *Contemporary Accounting Research*, 31, 1191-1219.

Stickells, C. (1980). *A Comparative Analysis of the Relationships of Price to Earnings and Price to Book Values*. (Master's Thesis, MIT).

Vasicek, O. A. (1973). A Note on using Cross-sectional Information in Bayesian Estimation of Security Betas. *The Journal of Finance*, 28(5), 1233-1239.

[Winter, P. et al. \(2014\). Investing in Value. UBS Investment Research](#)

[Winter, P. et al \(2015\). How will demographics shape investing for the next ten years? UBS Investment Research.](#)



## UBS Equity Quantitative Research publications

### Monographs

Title	Date
<a href="#">Dynamic Asset Allocation</a>	Nov-15
<a href="#">Who benefits from automation?</a>	Nov-15
<a href="#">The Spectre of Equity-Bond allocation</a>	Nov-15
<a href="#">Q-Series® How will demographics shape investing?</a>	Nov-15
<a href="#">Surfing the Macro Wave</a>	Sep-15
<a href="#">Why blame Risk-parity and CTAs?</a>	Sep-15
<a href="#">Cash or Shares? DRPs in Australia</a>	Sep-15
<a href="#">Bonds are better: asset allocation in target dated...</a>	Sep-15
<a href="#">Where are the best dividends?</a>	Aug-15
<a href="#">Low-risk investing: perhaps not everywhere</a>	Jul-15
<a href="#">Lessons from Behavioural Finance</a>	Jul-13
<a href="#">The madness of crowds</a>	Jul-15
<a href="#">Understanding Size Investing</a>	Jun-15
<a href="#">Safe dividends in times of financial repression</a>	Jun-15
<a href="#">Profiting from cross-asset seasonality</a>	Apr-15
<a href="#">Extending our quality model to Financials</a>	Mar-15
<a href="#">Stock selection using machine learning</a>	Jan-15
<a href="#">Where are the crowded trades?</a>	Jan-15
<a href="#">Investing in Growth</a>	Jan-15
<a href="#">Harvesting Cross-Asset Value</a>	Dec-14
<a href="#">How to avoid 'Torpedoes'</a>	Nov-14
<a href="#">US Quantitative Conference Highlights</a>	Nov-14
<a href="#">What happens when volatility normalises?</a>	Oct-14

### Academic Research Monitor

Topic	Date
<a href="#">Value Investing</a>	Dec-15
<a href="#">UBS Market Microstructure Conference</a>	Oct-15
<a href="#">Equity Risk Premium Forecasting &amp; Market Timing</a>	Sep-15
<a href="#">Behavioural Investing Patterns</a>	Jul-15
<a href="#">Quality and Size Investing</a>	May-15
<a href="#">UBS Quantitative Conference Highlights</a>	Apr-15
<a href="#">Smart Betas, Factors and Style Investing</a>	Feb-15
<a href="#">Momentum Investing</a>	Jan-15
<a href="#">Investment Strategies and Textual Analysis Signals</a>	Dec-14
<a href="#">Commodity Risk &amp; Institutional Investing Habits</a>	Nov-14
<a href="#">Index Membership, Investor (in)attention to News &amp; Spurious Correlations</a>	Sep-14
<a href="#">Forecasting the Equity Risk Premium</a>	Aug-14
<a href="#">Implied Cost of Capital &amp; Shorting Premium</a>	Jun-14
<a href="#">European Quantitative Conference Highlights</a>	May-14
<a href="#">Trend Following</a>	Mar-14
<a href="#">Factor investing &amp; Quality</a>	Feb-14
<a href="#">Quality &amp; Gross Profitability</a>	Jan-14
<a href="#">Minimum variance: valuation, concentration and exchange rates</a>	Dec-13
<a href="#">Liquidity &amp; back test overfitting</a>	Oct-13
<a href="#">News and its effect on asset prices</a>	Sep-13
<a href="#">Asset pricing &amp; skewness</a>	Aug-13
<a href="#">Timing momentum &amp; risk parity</a>	Jul-13

## UBS Quantitative Research Team

UK		US	
Nick Baltas	+44-20-7568 3072	Sebastian Lancetti	+1-203-719 4045
Maylan Cheung	+44-20-7568 4477		
Ian Francis	+44-20-7568 1872		
Josie Gerken	+44-20-7568 3560		
Simon Iley	+44-20-7568 6327		
David Jessop	+44-20-7567 9882		
Claire Jones	+44-20-7568 1873		
Manoj Kothari	+44-20-7568 1997		
Leon Schelhase	+44-20-7568 2346		
Simon Stoye	+44-20-7568 1876		
Christine Vargas	+44-20-7568 2409		
		Hong Kong	
		Josh Holcroft	+852-2971 7705
		Shanle Wu	+852-2971 7513
		Australia	
		Oliver Antrobus	+61-3-9242 6467
		Luke Brown	+61-2-9324 3620
		Pieter Stoltz	+61-2-9324 3779
		Paul Winter	+61-2-9324 2080

# Appendix A: Discounted FCF Model specification

In this monograph we use a four-stage discounted cash flow model with the following assumptions:

We use consensus forecast data for expected cash flows for the next 3-5 periods. Specifically, we use the IBES item called Free Cash Flow to Equity.

We use a discount rate determined by the traditional CAPM, except for a Vasicek (1973) adjustment made to the beta coefficient. The adjustment improves the statistical accuracy of the risk premium. The discount rate is specified as follows:

$$r = r_f + \beta_{vasicek}(r_m - r_f)$$

Where  $r_f$  is the yield on 10-year government bonds,  $r_m$  is the consensus 12 month forward earnings yield of the local market and  $\beta_{vasicek}$  is specified as follows:

$$\beta_{vasicek} = \frac{SE_{sector}^2}{SE_{sector}^2 + SE_{company}^2} \times \beta_{company} + \frac{SE_{company}^2}{SE_{sector}^2 + SE_{company}^2} \times \beta_{sector}$$

Where  $SE_{sector}$  is the standard error of all the company betas<sup>13</sup> for companies within a particular sector in cross-section,  $SE_{company}$  is the standard error of the company beta over time. The Vasicek (1973) adjustment applies the largest adjustment to those betas with the highest standard error and the least adjustment to those with the smallest.

We assume that cash flows grow at the expected rate of GDP growth into perpetuity. The growth rate is determined by the GDP model in our [recent work on demographics](#).

The above assumptions lead to the final version of the model, where we estimate the value of a company as:

$$V_0 = \frac{FCFE_1}{(1+r)^1} + \frac{FCFE_2}{(1+r)^2} + \frac{FCFE_3}{(1+r)^3} + \frac{FCFE_3 \times (1+g)}{(1+r)^3 \times (r-g)}$$


Where  $FCFE$  is the UBS or consensus free cash flow to equity forecast,  $r$  is the discount rate,  $g$  is the growth rate in perpetuity (which we proxy with the demographic-implied growth rate and inflation forecast as discussed in the paper) and  $t$  is an estimate of the time until  $FCFE$  is earned by the firm.

<sup>13</sup> We use a 5-year monthly beta calculated relative to the local market, supplied by FactSet.

## Appendix B: IC results


These results show the rank correlation between the Value model score and the subsequent return over the next 12 months. Financials are excluded.

**Figure 20: 12m rank IC – Asia ex Japan ex Financials – All Caps**




Source: UBS Quantitative Database. Universe is DJ Asia ex Japan, ex Financials.

**Figure 21: 12m rank IC – Asia ex Japan ex Financials – Large Caps**




Source: UBS Quantitative Database. Universe is MSCI AC Asia ex Japan, ex Financials.

**Figure 22: 12m rank IC – Europe ex Financials – All Caps**



Source: UBS Quantitative Database. Universe is DJ Europe, ex Financials.

**Figure 23: 12m rank IC – Europe ex Financials – Large Caps**




Source: UBS Quantitative Database. Universe is MSCI Europe, ex Financials.

## Appendix C: Backtest results


These results are cap-weighted and sector neutral unless otherwise stated. To form sector-neutral cap-weighted portfolios we reweight the portfolio back to benchmark sector weights e.g. if Utilities represent 10% of the benchmark then Utilities will form 10% of each portfolio. Results are calculating using long/short thirds portfolios, each side adjusted to be beta-neutral. Financials are excluded. Charts show the rolling 12m long-short return.

**Figure 24: 12m rolling returns – Asia ex Japan ex Financials – All Caps**




Source: UBS Quantitative Database. See the start of this section for detailed notes. Universe is DJ Asia ex Japan, ex Financials.

**Figure 25: 12m rolling returns – Asia ex Japan ex Financials – Large Caps**




Source: UBS Quantitative Database. See the start of this section for detailed notes. Universe is MSCI AC Asia ex Japan, ex Financials.

**Figure 26: 12m rolling returns – Europe ex Financials – All Caps**



Source: UBS Quantitative Database. See the start of this section for detailed notes. Universe is DJ Europe, ex Financials.

**Figure 27: 12m rolling returns – Europe ex Financials – Large Caps**



Source: UBS Quantitative Database. See the start of this section for detailed notes. Universe is MSCI Europe, ex Financials.

# Appendix D: Summary Statistics

Factors with a T-Statistic  $\geq 2$  are highlighted

Figure 28: Value Statistics

Cheap minus Everything						Cheap minus Expensive					
Cap Weighted	ValueModel	Return	Risk	Sharpe	TStat	ValueModel	Return	Risk	Sharpe	TStat	
Asia ex Japan - All Caps	FCFY Trail	2.4%	4.4%	0.55	1.55	FCFY Trail	9.0%	9.5%	0.94	2.66	
	Div Yld Fw d	3.9%	7.2%	0.54	1.51	Earn Yld Fw d	5.9%	10.0%	0.59	1.67	
	Earn Yld Fw d	2.9%	5.6%	0.52	1.47	DCF (Adj Beta)	6.8%	13.3%	0.51	1.43	
	Intrinsic	2.2%	5.5%	0.39	1.11	FCFY Fw d	4.1%	8.7%	0.47	1.31	
	BookYld	0.5%	6.8%	0.08	0.21	DCF (no TV)	5.0%	11.8%	0.42	1.19	
	DCF (Adj Beta)	-0.4%	10.7%	-0.04	-0.11	Div Yld Fw d	5.7%	14.9%	0.38	1.08	
	FCFY Fw d	-0.7%	7.1%	-0.10	-0.28	DCF (Vasicek Adj)	4.2%	11.6%	0.36	1.01	
	DCF (no TV)	-2.3%	9.7%	-0.23	-0.66	Intrinsic	3.0%	9.7%	0.31	0.88	
	DCF (Vasicek Adj)	-2.6%	10.5%	-0.25	-0.69	DCF (Lev Adj Ind Beta)	2.0%	10.9%	0.18	0.52	
DCF (Lev Adj Ind Beta)	-3.2%	9.6%	-0.33	-0.93	BookYld	0.2%	10.8%	0.02	0.05		
Cap Weighted	ValueModel	Return	Risk	Sharpe	TStat	ValueModel	Return	Risk	Sharpe	TStat	
Asia ex Japan - Large Caps	Intrinsic	4.2%	6.3%	0.67	1.88	DCF (Adj Beta)	11.6%	12.4%	0.94	2.64	
	Div Yld Fw d	3.9%	7.0%	0.56	1.57	DCF (no TV)	9.4%	10.9%	0.87	2.44	
	DCF (Adj Beta)	4.0%	9.2%	0.44	1.23	DCF (Vasicek Adj)	9.9%	11.7%	0.85	2.39	
	Earn Yld Fw d	2.5%	5.8%	0.43	1.21	DCF (Lev Adj Ind Beta)	7.1%	11.2%	0.64	1.79	
	BookYld	2.1%	6.9%	0.30	0.86	FCFY Trail	5.8%	9.5%	0.61	1.72	
	DCF (Vasicek Adj)	2.1%	8.6%	0.25	0.70	FCFY Fw d	4.7%	9.0%	0.52	1.46	
	FCFY Fw d	1.3%	6.1%	0.22	0.61	Div Yld Fw d	6.1%	12.3%	0.49	1.39	
	DCF (no TV)	1.7%	8.5%	0.20	0.57	Earn Yld Fw d	4.2%	10.5%	0.40	1.14	
	FCFY Trail	0.6%	4.6%	0.12	0.34	Intrinsic	3.3%	11.4%	0.29	0.82	
DCF (Lev Adj Ind Beta)	0.0%	8.6%	0.00	0.00	BookYld	1.2%	12.4%	0.09	0.26		
Cap Weighted	ValueModel	Return	Risk	Sharpe	TStat	ValueModel	Return	Risk	Sharpe	TStat	
Europe - All Caps	FCFY Trail	4.1%	4.4%	0.94	2.64	FCFY Trail	8.6%	7.7%	1.13	3.17	
	DCF (Vasicek Adj)	2.6%	8.3%	0.32	0.89	DCF (Vasicek Adj)	6.4%	13.7%	0.46	1.31	
	DCF (Adj Beta)	1.9%	8.1%	0.23	0.65	DCF (Lev Adj Ind Beta)	3.7%	13.0%	0.28	0.80	
	FCFY Fw d	0.0%	5.5%	0.01	0.02	FCFY Fw d	2.3%	8.2%	0.28	0.79	
	DCF (Lev Adj Ind Beta)	0.0%	6.8%	0.01	0.02	DCF (Adj Beta)	1.8%	10.7%	0.17	0.48	
	DCF (no TV)	-0.4%	8.6%	-0.04	-0.13	Div Yld Fw d	0.0%	9.4%	0.00	-0.01	
	Div Yld Fw d	-0.3%	4.9%	-0.07	-0.19	DCF (no TV)	-0.4%	10.7%	-0.03	-0.09	
	Intrinsic	-1.3%	6.0%	-0.22	-0.62	Earn Yld Fw d	-1.5%	7.7%	-0.19	-0.54	
	Earn Yld Fw d	-1.1%	4.4%	-0.25	-0.71	Intrinsic	-3.0%	10.3%	-0.29	-0.82	
BookYld	-2.0%	7.3%	-0.27	-0.77	BookYld	-4.4%	12.3%	-0.36	-1.00		
Cap Weighted	ValueModel	Return	Risk	Sharpe	TStat	ValueModel	Return	Risk	Sharpe	TStat	
Europe - Large Caps	FCFY Trail	4.3%	4.7%	0.92	2.59	FCFY Trail	8.7%	8.1%	1.07	3.02	
	DCF (Vasicek Adj)	3.7%	8.4%	0.44	1.24	DCF (Vasicek Adj)	7.3%	14.5%	0.51	1.42	
	DCF (Adj Beta)	0.9%	9.4%	0.10	0.28	DCF (Lev Adj Ind Beta)	3.4%	12.9%	0.26	0.74	
	Div Yld Fw d	0.5%	5.3%	0.10	0.28	FCFY Fw d	1.5%	8.4%	0.18	0.51	
	DCF (Lev Adj Ind Beta)	-0.7%	7.2%	-0.09	-0.26	Div Yld Fw d	0.9%	9.7%	0.09	0.26	
	DCF (no TV)	-1.2%	8.6%	-0.14	-0.38	DCF (Adj Beta)	0.1%	12.5%	0.01	0.03	
	FCFY Fw d	-0.8%	5.4%	-0.15	-0.43	DCF (no TV)	-2.1%	12.5%	-0.17	-0.47	
	Earn Yld Fw d	-1.2%	4.5%	-0.27	-0.76	Earn Yld Fw d	-1.9%	8.3%	-0.23	-0.65	
	Intrinsic	-1.6%	5.9%	-0.27	-0.76	Intrinsic	-3.3%	10.5%	-0.32	-0.90	
BookYld	-2.1%	6.2%	-0.33	-0.93	BookYld	-5.0%	11.9%	-0.42	-1.17		

Source: UBS Quantitative Database. Financials are excluded.

Figure 29: Value Statistics (Sector Neutral)

Cheap minus Everything						Cheap minus Expensive					
Cap Weighted	ValueModel	Return	Risk	Sharpe	TStat	Cap Weighted	ValueModel	Return	Risk	Sharpe	TStat
Asia ex Japan - All Caps	Earn Yld Fw d	3.5%	5.0%	0.69	1.95		Earn Yld Fw d	6.9%	9.3%	0.75	2.10
	Div Yld Fw d	4.2%	6.7%	0.62	1.76		FCFY Trail	5.9%	8.2%	0.72	2.03
	Intrinsic	2.6%	5.5%	0.48	1.35		Div Yld Fw d	8.7%	13.3%	0.65	1.84
	BookYld	2.0%	6.5%	0.31	0.86		Intrinsic	3.9%	9.4%	0.42	1.18
	FCFY Trail	0.6%	3.9%	0.15	0.42		DCF (no TV)	5.4%	13.3%	0.41	1.15
	FCFY Fw d	0.3%	7.3%	0.04	0.12		FCFY Fw d	2.5%	9.3%	0.27	0.75
	DCF (Vasicek Adj)	-4.5%	10.5%	-0.43	-1.22		BookYld	2.0%	9.6%	0.21	0.58
	DCF (no TV)	-4.5%	9.5%	-0.47	-1.34		DCF (Adj Beta)	2.4%	13.9%	0.18	0.50
	DCF (Adj Beta)	-5.5%	11.2%	-0.49	-1.38		DCF (Vasicek Adj)	1.8%	14.1%	0.13	0.37
	DCF (Lev Adj Ind Beta)	-7.3%	10.1%	-0.72	-2.02		DCF (Lev Adj Ind Beta)	-0.1%	12.6%	-0.01	-0.02
Cap Weighted Asia ex Japan - Large Caps	Earn Yld Fw d	3.6%	5.8%	0.63	1.78		DCF (no TV)	11.8%	10.5%	1.12	3.15
	Intrinsic	3.5%	5.8%	0.61	1.71		DCF (Vasicek Adj)	11.8%	11.8%	1.01	2.83
	Div Yld Fw d	3.4%	6.2%	0.54	1.51		DCF (Adj Beta)	8.5%	11.4%	0.75	2.11
	DCF (Vasicek Adj)	3.7%	9.0%	0.42	1.17		Earn Yld Fw d	6.5%	9.4%	0.69	1.95
	BookYld	2.5%	6.2%	0.40	1.13		DCF (Lev Adj Ind Beta)	5.9%	10.3%	0.57	1.61
	DCF (no TV)	2.5%	8.6%	0.29	0.82		Intrinsic	4.8%	10.0%	0.48	1.36
	FCFY Fw d	0.8%	6.2%	0.13	0.37		Div Yld Fw d	4.9%	11.5%	0.43	1.21
	DCF (Adj Beta)	1.0%	8.8%	0.12	0.32		FCFY Trail	3.5%	9.3%	0.37	1.05
	FCFY Trail	-0.5%	4.6%	-0.11	-0.32		FCFY Fw d	2.4%	9.6%	0.25	0.71
	DCF (Lev Adj Ind Beta)	-1.7%	8.2%	-0.20	-0.57		BookYld	1.9%	10.6%	0.18	0.49
Cap Weighted Europe - All Caps	FCFY Trail	1.8%	3.2%	0.57	1.60		FCFY Trail	5.9%	7.4%	0.79	2.22
	Earn Yld Fw d	1.0%	3.5%	0.29	0.80		DCF (Vasicek Adj)	4.6%	9.0%	0.51	1.43
	DCF (no TV)	2.2%	8.3%	0.26	0.73		DCF (Lev Adj Ind Beta)	2.5%	8.2%	0.31	0.86
	DCF (Vasicek Adj)	2.1%	8.5%	0.25	0.70		DCF (Adj Beta)	1.7%	9.8%	0.18	0.50
	DCF (Adj Beta)	1.0%	9.5%	0.11	0.30		DCF (no TV)	0.9%	10.7%	0.08	0.24
	DCF (Lev Adj Ind Beta)	0.7%	9.1%	0.08	0.21		Earn Yld Fw d	0.1%	6.6%	0.02	0.05
	BookYld	-0.1%	4.9%	-0.02	-0.04		Div Yld Fw d	0.0%	7.5%	0.00	0.01
	FCFY Fw d	-0.4%	6.0%	-0.06	-0.18		FCFY Fw d	-1.1%	8.4%	-0.13	-0.36
	Div Yld Fw d	-0.3%	3.6%	-0.09	-0.24		Intrinsic	-1.7%	7.8%	-0.22	-0.62
	Intrinsic	-0.7%	4.3%	-0.17	-0.48		BookYld	-2.0%	8.8%	-0.22	-0.62
Cap Weighted Europe - Large Caps	FCFY Trail	2.0%	3.1%	0.63	1.76		FCFY Trail	6.1%	8.2%	0.75	2.12
	DCF (no TV)	2.9%	8.5%	0.35	0.98		DCF (Vasicek Adj)	2.3%	9.8%	0.24	0.67
	Div Yld Fw d	0.9%	3.4%	0.25	0.71		Div Yld Fw d	1.7%	7.4%	0.23	0.66
	DCF (Vasicek Adj)	1.7%	9.6%	0.18	0.51		DCF (Lev Adj Ind Beta)	1.9%	8.8%	0.22	0.62
	Earn Yld Fw d	0.5%	3.5%	0.15	0.43		DCF (Adj Beta)	1.6%	9.6%	0.17	0.47
	DCF (Adj Beta)	1.2%	9.2%	0.13	0.36		DCF (no TV)	0.9%	10.8%	0.08	0.23
	DCF (Lev Adj Ind Beta)	0.9%	9.1%	0.10	0.27		Earn Yld Fw d	-0.1%	6.9%	-0.02	-0.04
	FCFY Fw d	0.5%	5.2%	0.09	0.25		FCFY Fw d	-1.5%	8.2%	-0.18	-0.51
	Intrinsic	-0.3%	4.1%	-0.07	-0.18		Intrinsic	-1.7%	8.1%	-0.21	-0.60
	BookYld	-1.1%	4.2%	-0.26	-0.73		BookYld	-2.9%	8.5%	-0.35	-0.97

Source: UBS Quantitative Database. Financials are excluded.



## **Statement of Risk**

Our quantitative models rely on reported financial statement information, consensus earnings forecasts and stock prices. Errors in these numbers are sometimes impossible to prevent (as when an item is misstated by a company). Also, the models employ historical data to estimate the efficacy of stock selection strategies and the relationships among strategies, which may change in the future. Additionally, unusual company-specific events could overwhelm the systematic influence of the strategies used to rank and score stocks.

## Required Disclosures

This report has been prepared by UBS Securities Australia Ltd, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit [www.ubs.com/disclosures](http://www.ubs.com/disclosures). The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission.

**Analyst Certification:** Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

### UBS Investment Research: Global Equity Rating Definitions

12-Month Rating	Definition	Coverage <sup>1</sup>	IB Services <sup>2</sup>
Buy	FSR is > 6% above the MRA.	49%	33%
Neutral	FSR is between -6% and 6% of the MRA.	40%	26%
Sell	FSR is > 6% below the MRA.	12%	18%
Short-Term Rating	Definition	Coverage <sup>3</sup>	IB Services <sup>4</sup>
Buy	Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.	less than 1%	less than 1%
Sell	Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.	less than 1%	less than 1%

Source: UBS. Rating allocations are as of 30 September 2015.

1:Percentage of companies under coverage globally within the 12-month rating category. 2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3:Percentage of companies under coverage globally within the Short-Term rating category. 4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

**KEY DEFINITIONS:** **Forecast Stock Return (FSR)** is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. **Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). **Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case. **Equity Price Targets** have an investment horizon of 12 months.

**EXCEPTIONS AND SPECIAL CASES:** **UK and European Investment Fund ratings and definitions are:** **Buy:** Positive on factors such as structure, management, performance record, discount; **Neutral:** Neutral on factors such as structure, management, performance record, discount; **Sell:** Negative on factors such as structure, management, performance record, discount. **Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with FINRA. Such analysts may not be associated persons of UBS Securities LLC and therefore are not subject to the FINRA restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

**UBS Securities Australia Ltd:** Oliver Antrobus, CFA; Paul Winter; Pieter Stoltz. **UBS Limited:** David Jessop.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.



## Global Disclaimer

This document has been prepared by UBS Securities Australia Ltd, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

Global Research is provided to our clients through UBS Neo, the UBS Client Portal and UBS.com (each a "System"). It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g. market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, your use shall be subject to this Global Research Disclaimer and to UBS's Terms of Use/Disclaimer (<http://www.ubs.com/global/en/legalinfo2/disclaimer.html>). By accessing and/or using Global Research in this manner, you are indicating that you have read and agree to be bound by our Terms of Use/Disclaimer. In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<http://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<http://www.ubs.com/global/en/homepage/cookies/cookie-management.html>).

**If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, transfer to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.**

For access to all available Global Research on UBS Neo and the Client Portal, please contact your UBS sales representative.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this document ('the Information'), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party.

Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. Investments involve risks, and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

This document and the Information are produced by UBS as part of its research function and are provided to you solely for general background information. UBS has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. In no circumstances may this document or any of the Information be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained in this document is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

**United Kingdom and the rest of Europe:** Except as otherwise specified herein, this material is distributed by UBS Limited to persons who are eligible counterparties or professional clients. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. **Germany:** Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). **Spain:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:** Distributed by UBS Limited. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce has contributed to this

document, the document is also deemed to have been prepared by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce. **Russia:** Prepared and distributed by UBS Bank (OOO). **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). **Italy:** Prepared by UBS Limited and distributed by UBS Limited and UBS Italia Sim S.p.A. UBS Italia Sim S.p.A. is regulated by the Bank of Italy and by the Commissione Nazionale per le Società e la Borsa (CONSOB). Where an analyst of UBS Italia Sim S.p.A. has contributed to this document, the document is also deemed to have been prepared by UBS Italia Sim S.p.A. **South Africa:** Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). **Israel:** This material is distributed by UBS Limited. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS Limited and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS Limited is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS Limited and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons. **Saudi Arabia:** This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **Dubai:** The information distributed by UBS AG Dubai Branch is intended for Professional Clients only and is not for further distribution within the United Arab Emirates. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate') to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. **Brazil:** Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM S.A. to persons who are eligible investors residing in Brazil, which are considered to be: (i) financial institutions, (ii) insurance firms and investment capital companies, (iii) supplementary pension entities, (iv) entities that hold financial investments higher than R\$300,000.00 and that confirm the status of qualified investors in written, (v) investment funds, (vi) securities portfolio managers and securities consultants duly authorized by Comissão de Valores Mobiliários (CVM), regarding their own investments, and (vii) social security systems created by the Federal Government, States, and Municipalities. **Hong Kong:** Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch. **Singapore:** Distributed by UBS Securities Pte. Ltd. [MCI (P) 018/09/2015 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. **Australia:** Clients of UBS AG: Distributed by UBS AG (Holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (Holder of Australian Financial Services License No. 231098). Clients of UBS Wealth Management Australia Ltd: Distributed by UBS Wealth Management Australia Ltd (Holder of Australian Financial Services License No. 231127). This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: [www.ubs.com/ecs-research-fsg](http://www.ubs.com/ecs-research-fsg). **New Zealand:** Distributed by UBS New Zealand Ltd. The information and recommendations in this publication are provided for general information purposes only. To the extent that any such information or recommendations constitute financial advice, they do not take into account any person's particular financial situation or goals. We recommend that recipients seek advice specific to their circumstances from their financial advisor. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. **Malaysia:** This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. **India:** Prepared by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, NSE (Currency Derivatives Segment) INE230951431, BSE (Capital Market Segment) INB010951437; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: [http://www.ubs.com/global/en/about\\_ubs/investor\\_relations/annualreporting.html](http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html)

The disclosures contained in research documents produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2016. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

